Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival
- PMID: 29558278
- DOI: 10.1200/JCO.2017.77.5643
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival
Comment in
-
Reply to P. Di Nardo et al and R. Sun et al.J Clin Oncol. 2018 May 1;36(13):1380-1381. doi: 10.1200/JCO.2018.78.0452. Epub 2018 Mar 20. J Clin Oncol. 2018. PMID: 29558276 No abstract available.
Comment on
-
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.J Clin Oncol. 2018 Feb 1;36(4):350-358. doi: 10.1200/JCO.2017.74.3245. Epub 2017 Dec 7. J Clin Oncol. 2018. PMID: 29215955 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical